
Resurgence of COVID 19 in India – what does it mean?
The SARS-Co-V2 that caused the COVID-19 pandemic did immeasurable harm to the world's population, socially, economically, psychologically. The pandemic continued in waves for about 3 years -- each wave driven by a different variant of the virus.
Covid phases and health impact
The first wave in 2020 was caused by the Wuhan virus that caused serious disease with hypoxia, clotting/bleeding problems and relatively moderate mortality. In India it started in March-April, peaked in September and abated by January 2021.
The second wave in 2021 was caused by the Delta variant that spread far more rapidly, producing an even more serious disease. It started in February, peaked in April and retuned to baseline by June. During those months it outran the health services and caused the greatest loss of life.
Memories of our experience, falling ill or watching family members or friends getting admitted in Intensive Care Units in hospitals, our elders dying in isolation, the agonising choice to take or not to take vaccine and which vaccine, lockdowns and school closures etc are still in our minds if not in the conscious level, certainly in the subconscious. Those nightmare memories are being brought forth in recent days, with the news of a resurgence of COVID-19. Electronic media keep reporting the resurgence on a daily basis, as if another wave is imminent. Truth is, no wave can occur, as we analyse the past.
The third wave was caused by the Omicron variant. It started in January 2022, peaked in February and abated in March. The pandemic ended in mid-2022, and thereafter the SARS-CoV-2, exclusively the Omicron variant, has remained everywhere in the world as 'endemic' meaning thereby: continuing and constant transmission in very small numbers. We have one more disease-causing virus in circulation than pre-pandemic. Most of us have forgotten the mildness of the third wave disease. The current resurgence is caused by the Omicron sub-variants -- and the anxiety during the first two waves is no longer necessary.
Variants and disease patterns
Incessant mutations are a feature of SARS-CoV-2. Most resultant variants are of no consequence but of curiosity for the molecular virologists. Some variants, as indicated by the missing alphabets (Greek) were of public health interest but not of concern. Three variants of Wuhan original – Beta, Delta and Omicron were of concern. The variants of concern had higher transmissibility and the ability to evade immunity than their predecessors that lost out in competition. Thus, Delta eliminated previous variants, and Omicron eliminated the Delta variant.
Infectiousness or transmissibility, can be measured. The average number of individuals infected by one infected person is denoted as the 'reproduction number' R. The higher the R, the more infectious the variant, and the faster and greater its spread. The original Wuhan variant had R of ~ 2, Delta had R of ~ 4, Omicron variant had R of ~ 8. The JN1 sub-variant of Omicron is said to have R of ~12 . The current NB.1.8.1 and XFG sub-variants must have even higher R value.
Between Delta and Omicron, there was a drastic change in disease pattern. Delta caused the classic COVID-19 in its worst form. The Omicron is much more mutated than the previous variants – think of it more as 'deviant' than variant, for two reasons: one, the unusually large number of mutations on the spike protein gene and second, its disease is just like a sore throat or upper respiratory tract disease.
The Omicron disease spares the lungs. It does not cause hypoxia, or bleeding/clotting disorders. It does not cause loss of smell – which is due to virus invasion of the smell apparatus, olfactory bulb. The biologic reason for the deviant behaviour is that Omicron's cell entry process is distinctly different from all other variants. Omicron infection does not cause fusion between adjacent cells – in technical terms syncytium formation.
Despite all these advantages, the virus is the same species and all the above are in relative terms. Even immunity evasion is only partial – any immunity from previous variants certainly makes the subsequent infection less severe. However, those with severe co-morbidities or old age with immune senescence or immunosuppression due to any disease or disease treatment can develop severe complications affecting several body organs and may require hospitalisation and even intensive care. For them, mortality can be high. But counting their deaths does not reflect the reality of virtually no mortality in healthy population.
Omicron also undergoes restless mutations, all denoted by English alphabets and numerals – they are mistakenly called variants by many, while they are all sub-variants. The currently highly prevalent subvariants including NB 1.8.1 and XFG (which is a recombinant of two earlier subvariants) are all derived from Omicron JN.1 sub-variant, and all the clinical features described for Omicron infection above are valid for all of them.
Drop in testing and the false sense of security
By August 2024 many countries stopped testing routinely for SARS-CoV-2 infection. That gave the false impression that the virus had stopped circulating. What happened recently, was that the countries that had continued testing reported the increasing trend of virus circulation, following which we also began testing – the more we tested, the more we found.
New-born infants, about 70,000 per day in India, adding up as annual birth cohorts constitute the immunity-naïve population pool for driving the continued virus circulation. But we know next to nothing about the frequency of infections in them.
Re-infection despite immunity is the norm for SARS-CoV-2. Omicron and its sub-variants became progressively more infective and had greater potential for spread. The recent number of COVID-19, reported as nearly 7,000, reflects the greater volume of testing, not the true magnitude of infection or disease in the population.
The Ministry of Health is monitoring the situation and has advised testing only for patients with influenza like illness (ILI) and patients admitted with severe acute respiratory illness (SARI). Because testing is selective, the reported numbers reflect more of those with significant symptoms than the true numbers of those with mild disease.
Immune escape
It is of note that successive variants of the virus have clearly demonstrated the 'immune escape' phenomenon. This immune escape is partly because immunity from previous infection and from previous vaccination wanes with time. Greater infectiousness is also due to the property of 'immune evasion' by the more successful variants and sub-variants. During the 2022 Omicron wave, most new infections were in those who had immunity from past infections or immunisation or both.
What is the likely outcome of this upsurge in cases?
The vast majority of those infected will have mild illness like a sore throat, dry cough (since lungs are not involved), fever, headache, etc. Some get mild diarrhoea too. By virtue of previous infection and or immunisation even the elderly and immunocompromised individuals also will mostly have a mild illness. A few individuals will develop pneumonia and will need hospital admission and out of these a small number will succumb. Management of these individuals should be along established lines with supportive treatment and steroids. Antiviral drugs are unlikely to be of much help.
As in all endemic viral infections, every upsurge will also peak and then decline after which the community will fall back into the steady state of endemic prevalence. What was surprising was the upsurge during high summer and very hot days. Most other respiratory viruses are more active during cooler times and rainy season.
The elderly and the immunocompromised individuals are well-advised to wear masks when they have to be in crowded places and during travel by bus, train or aeroplane. This precaution is necessary even at home if another family member has upper respiratory symptoms.
(Dr. M.S. Seshadri, is a retired professor of the department of endocrinology, diabetes and metabolism, Christian Medical College, Vellore. Email: mandalam.seshadri@gmail.com Dr. T. Jacob John, is a retired professor of clinical virology, Christian Medical College, Vellore. Email: tjacobjohn@yahoo.co.in)

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
an hour ago
- Time of India
Hay fever vs. COVID-19: How to tell the difference
Spring's in the air… and so is pollen. But these days, a runny nose or sneezing fit doesn't just make you reach for tissues—it makes you wonder, 'Wait… is this hay fever, or did I catch something worse?' Welcome to the age of allergy anxiety. COVID-19 is still hanging around in waves, and hay fever (aka allergic rhinitis) shows up like clockwork each year, causing sniffles, itchy eyes, and sinus pressure that weirdly feel suspiciously like early COVID symptoms. So how do you actually tell the difference? Hay fever isn't caused by hay and it's not a fever. It's an allergic response to pollen, dust mites, mold, or pet dander. Your immune system overreacts to these harmless particles like they're invaders, leading to inflammation in your nose, throat, eyes, and sinuses. I t's super common especially from late March to September when pollen counts go wild. Depending on where you live, tree pollen starts first, followed by grass, and finally weed pollen in late summer. The early symptoms Let's say you wake up with a scratchy throat and a mild headache. Cue panic. Here's where it gets confusing—both hay fever and COVID-19 can cause: A runny or blocked nose Sneezing Sore throat Tiredness Headache Cough (especially from postnasal drip in hay fever) But the why and how long behind the symptoms often differ. COVID-19 symptoms COVID tends to sneak in like a full-body invader. Early on, you might feel "off"—chills, muscle aches, fatigue that hits like a truck. Fever is a common red flag. And loss of taste or smell? That's a signature COVID move, especially if it happens suddenly without a blocked nose. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 오스템 임플란트 받아가세요 임플란터 더 알아보기 Undo COVID symptoms usually come on quickly and worsen over 2–3 days. You might start with a sore throat or fatigue, and then by day 2 or 3, you've got a hacking cough, fever, or worse. Key clues it's probably COVID-19: sudden loss of taste or smell, fever or chills, body aches, shortness of breath, nausea or diarrhea. Symptoms appear abruptly and get worse over a few days Hay fever is usually more of a face attack You'll feel it in your eyes, nose, and throat—sometimes even in your ears. Itchy, watery eyes are a classic giveaway. And the congestion or sneezing fits often follow a very predictable pattern—worse in the morning, better after a shower, or triggered by walking past a blooming tree. Plus, if it happens every spring or always gets worse when you mow the lawn, there's your answer. Key clues it's probably hay fever are itchy or watery eyes, no fever at all, symptoms are seasonal or triggered by outdoors. It improves with antihistamines and the sneezing fits or nasal itching that don't turn into body aches The sneeze test Yes, both conditions can make you sneeze. But hay fever sneezes usually come in bunches—like rapid-fire explosions. COVID-related sneezing is much less common. If your sneezing is uncontrollable and paired with itchy eyes or ears, that leans heavily toward hay fever. Taste and smell If you suddenly lose your ability to taste your coffee or can't smell your shampoo, but your nose isn't even that blocked, that's a huge red flag for COVID-19. In hay fever, smell and taste can dull a bit—but mostly because your nose is stuffed, not because the virus is messing with your nervous system. How to be sure: Rapid tests and allergy meds If you're still in doubt, take a COVID-19 rapid antigen test. They're quick, and they're a good first step. Another trick? Try an over-the-counter antihistamine. If your symptoms improve in an hour or two, it's likely hay fever. COVID doesn't care about allergy meds. Can you have both at once? Sadly, yes Just to make life harder, you can have COVID-19 and hay fever at the same time. If your allergies are flaring and suddenly you feel exhausted, feverish, or short of breath, don't chalk it all up to pollen. Test yourself, stay cautious, and isolate if needed. If you're someone who deals with allergies every spring like clockwork, and your symptoms feel just like last year, it's probably hay fever. But if something feels off, especially with fatigue or fever, don't wait—test and stay safe. One step to a healthier you—join Times Health+ Yoga and feel the change


Time of India
an hour ago
- Time of India
UAE scientists create paper test that diagnoses diseases in 10 mins, no lab needed!
UAE's 10-minute paper test can be quickly modified to detect COVID-19, malaria, dengue, chickenpox, and more/ Photo : Abu Dhabi Media Office A breakthrough in infectious disease testing is set to revolutionize the way healthcare is approached in low-resource and remote settings. A team of scientists at New York University Abu Dhabi (NYUAD) has unveiled a paper-based diagnostic tool, the Radially Compartmentalised Paper Chip (RCP-Chip), capable of detecting diseases in under 10 minutes. This innovation is a game-changer for fast, affordable, and portable disease screening without the need for complex lab equipment or trained personnel. Addressing the Global Need for Rapid Testing The RCP-Chip was conceived during the early days of the COVID-19 pandemic, when the world was grappling with a shortage of efficient testing methods, particularly in areas with limited resources. "Our goal was to create something fast, affordable, and easy to use, especially in areas where lab access is limited," said Mohammad A. Qasaimeh, Associate Professor of Mechanical Engineering and Bioengineering at NYUAD. Qasaimeh is the senior author of the study that led to the development of the RCP-Chip. The new tool offers a simple and rapid solution for detecting infectious diseases. "It uses a minimal number of reagents and requires only a small sample to run," Qasaimeh added, emphasizing the affordability and efficiency of the device. This paper-based diagnostic chip can be deployed easily in diverse settings, from remote villages to urban areas, and can significantly improve healthcare access. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Memperdagangkan CFD Emas dengan salah satu spread terendah? IC Markets Mendaftar Undo A Versatile Diagnostic Tool While the RCP-Chip was originally designed to detect COVID-19, its capabilities extend far beyond the novel coronavirus. According to Qasaimeh, the device is easily reconfigurable to diagnose other diseases such as chickenpox, dengue, malaria, and more. "With minor modifications, it can be adapted to diagnose a wide range of diseases or even test hormones and metabolites," Qasaimeh explained. This flexibility positions the RCP-Chip as a multi-purpose diagnostic tool that could be used in various medical fields, from general infectious disease testing to monitoring chronic health conditions. "What makes it truly impactful is its real-world potential," said Pavithra Sukumar, a Research Assistant at NYUAD and the co-first author of the study. Sukumar highlighted the tool's capacity to significantly improve outbreak responses, enabling faster isolation, treatment, and control. In situations where time is of the essence, such as in epidemic or pandemic scenarios, the rapid testing offered by the RCP-Chip can help curb the spread of diseases before they become uncontrollable. Simple, Cost-Effective, and Portable One of the standout features of the RCP-Chip is its portability. Unlike traditional diagnostic devices that require sophisticated lab setups, the chip can be operated with minimal resources. "It requires a heating stage at around 60 degrees Celsius, which can be easily achieved with common household devices like a hot plate or an oven," Qasaimeh explained. The simplicity of the design allows for easy transport and deployment, ensuring that healthcare workers in areas with limited infrastructure can use it effectively. Moreover, the RCP-Chip uses saliva samples instead of traditional swabs, making it even more convenient and comfortable for patients. "In a short amount of time, you can deploy it for use in almost any area," Qasaimeh said. This feature was a key motivation behind the development of the tool, aiming to reduce the time and cost typically associated with traditional diagnostic methods. From Concept to Commercialization The development of the RCP-Chip was not without its challenges. Due to pandemic-related lab access restrictions, the team faced delays during the initial stages of research. "In the initial phase, we focused on designing the chip and brainstorming the approaches," said Qasaimeh. It wasn't until restrictions were eased that the team was able to conduct in-depth testing of the device. "After initial curfews, gradually we were allowed access to labs, and that's when we deepened the research and began testing the device," he explained. Despite these challenges, the team successfully filed a patent for the device and launched a startup to commercialize it. Biotech companies have already expressed interest in the innovation. "We aim to find investors so that we can continue with the development stage of the device," Qasaimeh added. The focus now is on bringing the device to market and further developing its translational potential, ensuring that it can be adapted for various purposes in the healthcare sector. With the growing demand for affordable and effective diagnostic tools, the RCP-Chip is poised to play a pivotal role in global healthcare. Its low cost, speed, and versatility make it an ideal solution for resource-limited settings, providing a much-needed alternative to current testing methods.


Time of India
4 hours ago
- Time of India
Isolated COVID cases reported in Rajasthan, Madhya Pradesh; officials say situation under control
Jaipur: Health authorities in Rajasthan and Madhya Pradesh have reported a mild uptick in COVID-19 cases, though officials assert that the situation remains under control with no indication of widespread concern. In Rajasthan, Dr Ravi Prakash Sharma, Director of the Department of Medical, Health & Family Welfare, said that the state is currently seeing "30 to 35 new COVID-19 cases every day", with one death recorded so far. "We are seeing 30-35 cases of Covid every day in the state. We have sufficient stock of medicines," he said. Dr Sharma added that the deceased patient also suffered from tuberculosis and that the state has adequate supplies of medicines and is closely monitoring the situation. Meanwhile, in Gwalior, Madhya Pradesh, authorities at Gajra Raja Medical College have reported multiple COVID-19 cases among medical staff, including junior doctors. Dr RKS Dhakad, the institution's dean, stated that 6 to 7 junior doctors have tested positive but reassured that all cases are mild and under observation. "Several tests have returned positive, including some junior doctors. The situation is not serious. Guidelines have already been issued," Dr Dhakad told reporters. According to the Ministry of Health and Family Welfare's official dashboard, as of June 13, India reported 7,131 active COVID-19 cases and 10,976 recoveries. Earlier on June 11, Uttar Pradesh Deputy Chief Minister Brajesh Pathak stated that full arrangements had been made to handle the COVID-19 cases in the state. He further stated that reviews had been conducted and that all necessary preparations had been made for oxygen plants and hospitals in the state. "There is no need to panic. Experts have said that, for now, it is limited to cold and fever. Only serious patients and the elderly need to be cautious. The government has made full arrangements. Reviews are being conducted at every level, and in addition, we have ensured all necessary preparations in oxygen plants and hospitals," Pathak told ANI. On May 28, the UP government issued an order to keep more than 2800 employees who had worked during the previous COVID time in permanent service.